Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

Jumbo’s FY25 Growth Potential Under A Cloud

Jul 10 2024

Jumbo Interactive has been benefiting from a run of big lottery jackpots, but is this a trend or a blip? Citi has concerns, initiating coverage with a Sell rating


Twists And Turns Of Telix And Australian Biotech

Jul 10 2024

In the wake of Telix Pharmaceuticals’ non-IPO on the Nasdaq, FNArena shines a light on the company’s fortunes and that of Australian biotech and cancer research generally


Ventia Services: Unique Mix Of Growth & Defence

Jul 09 2024

Analysts highlight structural tailwinds for Ventia Services and margin protection from contract mix and flexible costs


Zip Co, The Lazarus Of BNPL

Jul 05 2024

Following its near-death experience last year, BNPL provider Zip Co has made a strong comeback. Evans & Partners has initiated coverage


Strong Growth Underpins Superloop Optimism

Jul 04 2024

Superloop management has raised FY24 earnings guidance and confirmed the Origin Energy customer transition is on track. Analysts see additional growth opportunities


Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024

The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising


Building The No 3 Diagnostic Imaging Player

Jun 19 2024

Brokers highlight deregulation and scale benefits from the potential merger of Integral Diagnostics and Capitol Health


Deterra Seeks Growth Through Diversification

Jun 18 2024

Deterra Royalties is looking to diversify away from iron ore royalties and provide for growth, in lithium in particular. The trade-off is a much-reduced dividend yield


Codan’s Communication Upside

Jun 18 2024

Codan has surprised with the performance of its metal detection business, but it is the company’s communications business that has brokers excited


Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024

The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports



Analyse The Market From A Different Angle